Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
We compared patients seen by the ALivE service (intervention) at Massachusetts General Hospital to those who received standard of care at our neighboring, tertiary-care hospital (Brigham and Womens Hospital) over the same time period of 2020-2024
Sometimes, if you have other weight-related health issues, a BMI of 27 or higher might be enough for consideration
Emerging candidates in late-stage development include CagriSema (semaglutide combined with cagrilintide, an amylin analog), retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors), and orforglipron (a non-peptide oral GLP-1 agonist that does not require the fasting restrictions of Rybelsus)
Who cannot take tirzepatide
We did a full webinar breaking down the topicmembers can access the recording on-demand , and download all the graphics from the session here
US$ 24.83
US$ 22.87
)
US$ 27.46
US$ 26.31
US$ 27.61
